Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4.7 Supplemental Indenture 5.75% 2022 Notes
- 4.9 Supplemental Indenture 7.25% 2022 Notes
- 4.12 Supplemental Indenture 2023 Notes
- 4.15 Supplemental Indenture 2025 Notes
- 10.28 Novartis License Agreement
- 10.32 Final Indemnification Agreement
- 10.33 Executive Employment Agreement
- 10.18.1 Biospecifics Technologies Amendment to 2ND Development and License Agreement
- 21.1 Subsidiaries
- 23.1 Consent of PWC LLP
- 23.2 Consent of Deloitte and Touche LLP
- 24.1 Power of Attorney
- 31.1 CEO Section 302 Certification
- 31.2 CFO Section 302 Certification
- 32.1 CEO Section 906 Certification
- 32.2 CFO Section 906 Certification
- Download Excel data file
- View Excel data file
Related press release
ENDPQ similar filings
Filing view
External links